Wealthspire Advisors (Maryland)’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-25	Closed	-$1K	–	2179
2019 Q1	$1K	Hold	25	–	–	﹤0.01%	2420
2018 Q4	$1K	Hold	25	–	–	﹤0.01%	2362
2018 Q3	$2K	Hold	25	–	–	﹤0.01%	2216
2018 Q2	$2K	Hold	25	–	–	﹤0.01%	2222
2018 Q1	$2K	Buy	+25	New	+$3.72K	﹤0.01%	2237

Other funds holding NBSE

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MIG

Mariner Investment Group Harrison, New York $463M AUM 13.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

SSB

Sandy Spring Bank Olney, Maryland $2.38B AUM 8.14% 1-Year Est. Return

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s NBSE Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2019, closing a stake of 25 shares — an estimated $1K sold.

Wealthspire Advisors (Maryland) first reported a position in NBSE in Q1 2018 and held it in 5 quarters. The position peaked at $2K in Q3 2018. 13 funds tracked by Wall St. Rank hold NBSE as of Q2 2019.

Wealthspire Advisors (Maryland) reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 25 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $1K.
Wealthspire Advisors (Maryland) first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
Wealthspire Advisors (Maryland)'s NeuBase Therapeutics, Inc. Common Stock position peaked at $2K in Q3 2018.
13 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.